CoChat
Sign Up
Cited by 231Erythropoietin and Anemia TreatmentHormonal and reproductive studiesIron Metabolism and Disorders

Androgens and erythropoiesis: past and present

Shahani, S., Braga-Basaria, M., Maggio, M., Basaria, S.·2009·Journal of Endocrinological Investigation
DOI 10.1007/bf03345745
Open this paper in CoChat — free account

Abstract

Association between androgens and erythropoiesis has been known for more than seven decades. Androgens stimulate hematopoietic system by various mechanisms. These include stimulation of erythropoietin release, increasing bone marrow activity and iron incorporation into the red cells. Before the discovery of recombinant erythropoietin (rhEpo), androgens were used in the treatment of anemia associated with renal disease, bone marrow suppression, and hypopituitarism. Anabolism is an additional advantage of androgen therapy. Furthermore, in light of recent reports regarding adverse effects of rhEpo, the role of androgen therapy in various types of anemias should be readdressed. Polycythemia remains a known side effect of androgen therapy. In this review, we will briefly discuss the initial animal and human studies which demonstrated the role of androgens in the treatment of anemia, their mechanism of action, a detailed account of the efficacy of androgens in the treatment of various anemias, the erythropoietic side effects of androgens and finally, the relationship between hematocrit levels and cardiovascular disease.

Integrity signals

Registry

Crossref · 10.1007/bf03345745

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The sex difference in circulating hemoglobin levels is likely due to the sex difference in average circulating testosterone concentrations.

    “The proposition that the sex difference in circulating hemoglobin levels is likely to be due to the sex difference in average circulating testosterone concentrations is supported by the fact that male castration (e.g., for advanced prostate cancer) (126) and androgen deficiency due to reproductive system disorders (127) reduce circulating hemoglobin in men, eliminating the sex difference, whereas”

    From Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance (2018) · cites this paper as [121]

  • Circulating hemoglobin levels are higher in men than in women by 12% on average.

    “It is well known that levels of circulating hemoglobin are androgen-dependent and consequently higher in men than in women by 12% on average; however, the physiological mechanism by which androgens such as testosterone boosts circulating hemoglobin is not fully understood (121).”

    From Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance (2018) · cites this paper as [121]

  • Circulating hemoglobin levels are androgen-dependent.

    “It is well known that levels of circulating hemoglobin are androgen-dependent and consequently higher in men than in women by 12% on average; however, the physiological mechanism by which androgens such as testosterone boosts circulating hemoglobin is not fully understood (121).”

    From Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance (2018) · cites this paper as [121]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Shahani, S., Braga-Basaria, M., Maggio, M., & Basaria, S.
Affiliations
  • Baylor College of Medicine (US)
  • University of Parma (IT)
  • Boston University (US)
Corresponding author
Basaria, S.
ORCID
Basaria, S.
Venue
Journal of Endocrinological Investigation
Publisher
Springer Science and Business Media LLC
Published
2009-04-07
Volume
32
Issue
8
Pages
704-716
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
DOI
10.1007/bf03345745
OpenAlex
W2037083937
Cited by
231
References
184
Citations by year
2026: 12 · 2025: 13 · 2024: 12 · 2023: 21 · 2022: 19 · 2021: 21 · 2020: 21 · 2019: 20 · 2018: 11 · 2017: 12 · 2016: 11 · 2015: 15 · 2014: 11 · 2013: 15 · 2012: 5
FWCI
0.83
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Endocrinological Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords
androgens, erythropoiesis, anemia, erythropoietin, recombinant human erythropoietin, myelosuppression, hypopituitarism, polycythemia, hematocrit, cardiovascular disease, iron incorporation, anabolic effects
MeSH terms
Aging, Androgens, Anemia, Anemia, Aplastic, Animals, Bone Marrow, Coronary Disease, Erythrocytes, Erythropoiesis, Erythropoietin, Female, Humans, Iron, Kidney Failure, Chronic, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review